Editas Medicine, Inc.
EDIT Healthcare Biotechnology
Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.
Follow EDIT
Editas Medicine, Inc. (EDIT) P/E ratio
Editas Medicine, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 41 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ENTX Entera Bio Ltd. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| EDIT Editas Medicine, Inc. | n/m |
| SPRY ARS Pharmaceuticals, Inc. compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| CAPR Capricor Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.6× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)